New urine test could spare bladder cancer patients from failed treatments
NCT ID NCT04564781
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study is testing a new urine test that aims to predict whether bladder cancer patients will respond well to a standard treatment called BCG. Currently, about half of patients do not respond to BCG, leading to extra treatments or bladder removal. The test looks for specific markers in urine and will be checked against standard cystoscopy results. The goal is to help doctors choose the right treatment from the start, avoiding ineffective therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
-
Kyoto University
RECRUITINGKyoto, 606-8501, Japan
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
-
UCSF
RECRUITINGSan Francisco, California, 94143, United States
-
University of Queensland
RECRUITINGBrisbane, Australia
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Could a simple blood or urine test spot bladder cancer earlier?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Can heated chemotherapy beat bladder cancer without surgery?
- Bladder cancer: a new combo aims to avoid radical surgery
- Could a simple urine test spare bladder cancer patients from chemotherapy?